Menu
Back to Journals » ClinicoEconomics and Outcomes Research » Volume 9
Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
Authors Restelli U , Fabbiani M , Di Giambenedetto S, Nappi C , Croce D
Received 6 June 2017
Accepted for publication 24 July 2017
Published 27 September 2017 Volume 2017:9 Pages 569—571
DOI https://doi.org/10.2147/CEOR.S143377
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Giorgio Colombo
Umberto Restelli,1,2 Massimiliano Fabbiani,3 Simona Di Giambenedetto,3 Carmela Nappi,4 Davide Croce,1,2
1Center for Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, Italy; 2School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 3Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, 4Health Economics, Bristol Myers Squibb S.r.l., Rome, Italy
In 2017, the authors published an article to assess the financial consequences for the Italian National Health Service, over a 5-year period, of the adoption of a simplification strategy to atazanavir (ATV) + ritonavir (r) + lamivudine (3TC) dual therapy of HIVpositive patients receiving ATV plus two nucleoside reverse transcriptase inhibitors (NRTIs) starting from data of the Atlas-M trial at 48 weeks.1
Consequently to the publication of the clinical results of the Atlas-M trial at 96 weeks, we updated the model implemented for the analysis, considering the most recent evidence.2
The model was adapted considering the transitions among antiretroviral therapies (ARTs) observed in the trial, as reported in Figure 1, for years 1 and 2, and maintaining for years 3, 4, and 5 the same differential effectiveness (percentage of patients without virologic failure) observed between 48 and 96 weeks. In detail, the percentage of virologic failures considered in year 1 were 4.51% for ATV+r+2 NRTI and 0.76% for ATV+r+3TC; and in each following year were 8.66% for ATV+r+2 NRTI and 3.05% for ATV+r+3TC.
Acknowledgments
We would like to thank the Atlas-M Study Group for their contribution in sharing the clinical Atlas-M data. The analysis was supported by an unconditional grant from Bristol Myers Squibb.
Disclosure
UR declares speaker fees (Janssen Cilag, Abbvie, Gilead). MF received speakers’ honoraria and support for travel to meetings from Bristol Myers Squibb, Gilead, Merck Sharp & Dohme, ViiV Healthcare, and Janssen-Cilag. SDG declares speakers’ honoraria and support for travel to meetings from Bristol Myers Squibb, Gilead, Merck Sharp & Dohme, ViiV Healthcare, and Janssen-Cilag. CN is employed by Bristol Myers Squibb S.r.l. DC declares advisory board fees (Merck Sharp & Dohme, Abbvie). The authors report no other conflicts of interest in this work.
References
Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D. Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial. Clinicoecon Outcomes Res. 2017;9:173–179. Erratum in: Clinicoecon Outcomes Res. 2017;9:231. | ||
Gagliardini R, Fabbiani M, Quiros Roldan E, et al. Simplification to atazanavir/ritonavir lamivudine versus maintaining atazanavir/ritonavir 2NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trial. Glasgow Congress on HIV Therapy, 23–26 October 2016. Oral abstract O121. |
© 2017 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.